How were Derma Sciences' earnings last quarter?

Derma Sciences Inc (NASDAQ:DSCI) released its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.16. The medical instruments supplier had revenue of $22.20 million for the quarter, compared to analyst estimates of $22.40 million.

What other stocks do shareholders of Derma Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Derma Sciences investors own include Novavax (NVAX) , Progenics Pharmaceuticals (PGNX) , Palatin Technologies (PTN) , Allena Pharmaceuticals (ALNA) , Antares Pharma (ATRS) , Fate Therapeutics (FATE) , Genetic Technologies (GENE) , Genocea Biosciences (GNCA) , Idera Pharmaceuticals (IDRA) and Molecular Templates (MTEM) .

NASDAQ:DSCI

Derma Sciences (DSCI) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free DSCI Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $7.00
▼
$7.00
50-Day Range: N/A
52-Week Range: $2.92
▼
$7.05

Volume: N/A
Average Volume: 719,592 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Derma Sciences alerts:

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

About Derma Sciences Stock (NASDAQ:DSCI)

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Ad InvestorPlace

Nerd Investor Reveals Secret To Make Money With A.I.

He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.

>>Check out what this A.I. Perfect Storm is<<

DSCI Stock News Headlines

April 12, 2024 | msn.com

Successful murine model of dermatomyositis reveals underlying immune system involvement

February 22, 2024 | msn.com

Decoding dermatomyositis: All you need to know

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

January 17, 2024 | msn.com

Attain your skincare resolutions with these top dermatologists in 2024

October 25, 2023 | msn.com

Dermatologists To Look Up to This Festive Season

August 30, 2023 | forbes.com

India's Cyber Security Startups Are Gaining Traction, Thanks To Demonetization

May 2, 2023 | news.yahoo.com

Looking to 'change history,' Japan's Derma Sotogake, Continuar work toward Kentucky Derby

February 13, 2023 | nypost.com

The 7 is best derma rollers for microneedling, with dermatologists’ tips

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

August 24, 2022 | finance.yahoo.com

Dermavant to Present New Data from Phase 3 Trial Program of VTAMA® (tapinarof) cream, 1% for Adults with Plaque Psoriasis at the 2022 EADV Congress

August 2, 2022 | finance.yahoo.com

DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections

July 27, 2022 | seekingalpha.com

Derma Sciences Inc. (DSCI) CEO Jan De Witte on Q2 2022 Results - Earnings Call Transcript

July 27, 2022 | apnews.com

CORRECTION: Independent Laboratory Test Results Confirm Value of DermaPreciseTM Injection Consistency in Clinical Simulation Testing

See More Headlines

Receive DSCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Derma Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/09/2016
Today: 4/16/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: Health Care Supplies
Current Symbol: NASDAQ:DSCI
CUSIP: 24982750
CIK: 892160
Web: www.dermasciences.com
Phone: +1-609-5144744
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

DSCI Stock Analysis - Frequently Asked Questions

How were Derma Sciences' earnings last quarter?: Derma Sciences Inc (NASDAQ:DSCI) released its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.08) by $0.16. The medical instruments supplier had revenue of $22.20 million for the quarter, compared to analyst estimates of $22.40 million.
What other stocks do shareholders of Derma Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Derma Sciences investors own include Novavax (NVAX), Progenics Pharmaceuticals (PGNX), Palatin Technologies (PTN), Allena Pharmaceuticals (ALNA), Antares Pharma (ATRS), Fate Therapeutics (FATE), Genetic Technologies (GENE), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA) and Molecular Templates (MTEM).

This page (NASDAQ:DSCI) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Derma Sciences (DSCI) Stock Price, News & Analysis

About Derma Sciences Stock (NASDAQ:DSCI)

DSCI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

DSCI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info